Excision’s HIV gene editing clinical trial; Nykode’s $45M placement; Ideaya’s post-ESMO offering

Plus, news from Skye Bio­science, Me­di­ar Ther­a­peu­tics and Servi­er.

A first look at Ex­ci­sion’s HIV gene edit­ing clin­i­cal tri­al: The com­pa­ny said Wednes­day that three pa­tients have been dosed in the Phase I/II study so far, with mild grade 1 side ef­fects re­lat­ed to the ther­a­py, known as EBT-101. Two of the three par­tic­i­pants ex­pe­ri­enced brief el­e­va­tion in liv­er en­zymes, a con­cern re­lat­ed to ther­a­pies like EBT-101 that use vi­ral vec­tors for de­liv­ery. How­ev­er, there were no in­fu­sion-re­lat­ed re­ac­tions or com­ple­ment-me­di­at­ed tox­i­c­i­ty, a type of im­mune re­sponse. The re­sults were pre­sent­ed at the Eu­ro­pean So­ci­ety of Gene & Cell Ther­a­py’s an­nu­al meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.